(Reuters) - Eli Lilly and Co's experimental pill for rheumatoid arthritis proved superior to Abbvie Inc's leading injectable Humira treatment in a large study, which analysts said could prod them to raise sales forecasts for the medicine.
from Reuters: Science News http://ift.tt/1OBLJmO
via IFTTT
No comments:
Post a Comment